AMRX Amneal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSE: AMRX

Price (delayed)

$4.17

Market cap

$1.28B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.02

Enterprise value

$4.02B

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in ...

Highlights
AMRX's EPS has soared by 98% since the previous quarter and by 98% year-on-year
The company's net income has surged by 98% QoQ and by 98% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amneal.com
Peers: OGN

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
306.31M
Market cap
$1.28B
Enterprise value
$4.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4
Price to sales (P/S)
0.28
EV/EBIT
21.06
EV/EBITDA
9.38
EV/Sales
1.74
Earnings
Revenue
$2.31B
EBIT
$190.96M
EBITDA
$428.89M
Free cash flow
$147.11M
Per share
EPS
-$0.02
Free cash flow per share
$0.96
Book value per share
$1.04
Revenue per share
$15.04
TBVPS
$13.57
Balance sheet
Total assets
$3.7B
Total liabilities
$3.55B
Debt
$2.86B
Equity
$318.17M
Working capital
$644.44M
Liquidity
Debt to equity
8.98
Current ratio
1.83
Quick ratio
1.02
Net debt/EBITDA
6.4
Margins
EBITDA margin
18.6%
Gross margin
34.9%
Net margin
-0.1%
Operating margin
8.3%
Efficiency
Return on assets
-0.1%
Return on equity
-0.7%
Return on invested capital
4.7%
Return on capital employed
6.5%
Return on sales
8.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
-2.8%
1 week
-2.8%
1 month
6.65%
1 year
104.41%
YTD
109.55%
QTD
34.52%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.31B
Gross profit
$807.83M
Operating income
$191.81M
Net income
-$2.05M
Gross margin
34.9%
Net margin
-0.1%
The company's net income has surged by 98% QoQ and by 98% YoY
AMRX's net margin has surged by 98% year-on-year and by 98% since the previous quarter
AMRX's revenue is up by 9% year-on-year
The company's gross profit rose by 9% YoY and by 2.5% QoQ

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
4
P/S
0.28
EV/EBIT
21.06
EV/EBITDA
9.38
EV/Sales
1.74
AMRX's EPS has soared by 98% since the previous quarter and by 98% year-on-year
The price to book (P/B) is 96% higher than the last 4 quarters average of 2.1 but 14% lower than the 5-year quarterly average of 4.8
Amneal Pharmaceuticals's equity has increased by 13% YoY and by 8% QoQ
The price to sales (P/S) is 190% higher than the last 4 quarters average of 0.1 but 42% lower than the 5-year quarterly average of 0.5
AMRX's revenue is up by 9% year-on-year

Efficiency

How efficient is Amneal Pharmaceuticals business performance
Amneal Pharmaceuticals's return on equity has surged by 98% QoQ and by 98% YoY
The company's return on assets has surged by 97% QoQ and by 97% YoY

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 4.2% greater than its total liabilities
AMRX's quick ratio is up by 29% YoY and by 3% from the previous quarter
The company's current ratio rose by 17% YoY
The company's debt to equity fell by 13% YoY and by 7% QoQ
Amneal Pharmaceuticals's equity has increased by 13% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.